Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn’s Disease: A Post Hoc Analysis of the SEAVUE Trial
Baseline MM-SES-CD-based cutoffs for endoscopic disease severity show prognostic value for the likelihood of achieving 1-year EH, PRO2 remission, and FCP remission. These findings suggest that the MM-SES-CD can be used both to measure baseline endoscopic disease severity and predict outcomes at 1 year in patients with moderate to severe CD.
Authors
- Sama Anvari (ORCID: https://orcid.org/0000-0002-7284-8735)
- Emily C L Wong (ORCID: https://orcid.org/0000-0001-9472-201X)
- Vipul Jairath (ORCID: https://orcid.org/0000-0001-8603-898X)
- Walter Reinisch (ORCID: https://orcid.org/0000-0002-2088-091X)
- Dhruv Ahuja
- John K. Marshall (ORCID: https://orcid.org/0000-0002-0523-9032)
- Parambir Dulai
- Neeraj Narula (ORCID: https://orcid.org/0000-0002-1536-8436)
Institutions
- Northwestern University (US)
- Western University (CA)
- Institut de Recherche en Santé Digestive (FR)
- Indira Gandhi Delhi Technical University for Women (IN)
- Indira Gandhi National Open University (IN)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1093/ibd/izaf137
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82